Ceribell Posts Strong Revenue Beat Amidst Accelerated Losses
Medical technology firm Ceribell Inc (NASDAQ:CBLL) reported its fourth-quarter and full-year 2025 financial results after the market close on Monday, delivering a significant top-line beat against analyst expectations while its net loss widened year-over-year. The company, which provides a portable EEG system for acute neurological care, continues to demonstrate rapid revenue growth fueled by expanding its hospital account base.
Earnings and Revenue Versus Estimates
For the critical fourth quarter, Ceribell’s performance against Wall Street forecasts presents a mixed but growth-oriented picture.
- Revenue: The company reported Q4 revenue of $24.8 million, surpassing the analyst consensus estimate of approximately $24.4 million. This represents a 34% increase from the $18.5 million reported in the same quarter last year.
- Earnings Per Share (EPS): The reported net loss per share was -$0.36. This figure came in better than the more pessimistic analyst estimate of a -$0.42 loss per share.
The full-year results echoed this trend of robust sales growth coupled with mounting operating expenses. Annual revenue reached $89.1 million, a 36% jump from 2024. However, the net loss for the year expanded to $53.4 million, or -$1.46 per share, compared to a net loss of $40.5 million, or -$3.39 per share, in the prior year. The improvement in per-share loss is attributed to a significant increase in the weighted-average share count year-over-year.
Market Reaction and Price Action
Following the earnings release, the market’s immediate reaction in after-hours trading was neutral, with the stock price showing negligible movement. This muted response suggests investors had largely priced in the company’s growth trajectory and ongoing losses. However, a broader view of recent performance provides more context:
- The stock has declined approximately 9.8% over the past month.
- It is down 4.8% over the past two weeks.
This recent weakness likely reflects broader market sentiment and profit-taking ahead of the earnings announcement, rather than a specific reaction to the just-released figures. The post-earnings stability indicates the results were largely in line with or slightly better than tempered expectations.
Key Highlights from the Earnings Report
Beyond the headline numbers, Ceribell’s press release emphasized several operational and regulatory milestones achieved in what CEO Jane Chao called a "milestone year."
- Account Growth: The company ended 2025 with 647 total active accounts, driving expansion in both product and subscription revenue streams.
- Strong Profitability Metrics: Gross margins remained exceptionally high at 87% for the quarter and 88% for the full year.
- Regulatory Progress: Ceribell received multiple FDA clearances, including for a continuous monitoring solution for delirium and for extending its Clarity seizure detection algorithm to neonatal patients. It also received Breakthrough Device Designation for a stroke detection tool.
- 2026 Financial Outlook: Management provided revenue guidance for the full year 2026 in the range of $111 million to $115 million. This outlook, which implies 25% to 29% year-over-year growth, appears conservative compared to the current analyst sales consensus estimate of approximately $114.9 million for 2026.
Balance Sheet and Path Forward
Ceribell reported a solid cash position of $159.3 million in cash, cash equivalents, and marketable securities as of December 31, 2025. This war chest is crucial as the company continues to invest heavily in its commercial organization, research and development, and general administrative functions to scale the business. The increased operating expenses, which rose 42% for the full year, are explicitly tied to these growth investments.
The company’s strategy hinges on converting its recent FDA clearances into commercial wins and deeper penetration within existing hospital accounts. The reiterated long-term vision of "making EEG a new vital sign" underscores its ambition to move beyond niche monitoring to become a standard of care in acute settings.
For a detailed breakdown of future quarterly estimates and historical earnings performance, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.